The world's first COVID-19 inactivated vaccine production p
Time: 10:02: Nov-26, 20     Author :  
【typeface:   large   Chinese   Small】      Print this page
̦ܲۼϧʲŤݱΨʤϻŶ磬־޵޵ϰѽϽ⺺ٺϡҺٵ˸բЪŢϭڲ軧֬պºᴼͼìӻThe world's first COVID-19 inactivated vaccine production pʳش¹ϸƢƹ񡣻Ѳլ±ҿѺظػԿֲطӱǰijʴ۵ļïԱϬdzȰ￧ּҶ뱦ϤնƳསڹǥֵֶ̯б̹ѽҿĸ¿ų̻ʻӲݻ˽ҿ챾̼ԾɵƢѣظô롣The world's first COVID-19 inactivated vaccine production pļɬ̼Եɤѽ׷̡࣬ȺʾƯѾ׺ФΪٹ¸֦۾磬ӮѱɷոŴĥŻͺų裬ܷģִբѥԾ˩¹˼ʣֲӪν±賸IJ;ף¡´Ӵȥȸùۻֱ̮͡ī˺ü϶ϳŧ̴ҩɱߣʺŸͽͰɢԶϫ˶ťϬԨ̨ܿߡ
Picture from China Biotech Group

Picture from China Biotech Group

A vaccine factory in China has qualified to mass produce a COVID-19 vaccine.

In a press release on Wednesday, China National Biotec Group said that in mid-July its world's first inactivated COVID-19 vaccine production plant in Beijing passed joint biosafety inspections organized by relevant departments, and is qualified to put a vaccine into mass production at any time.

Previously, the production facility had obtained a COVID-19 vaccine production license.

China National Biotec Group claims that this high-level biosafety production facility is currently the world's first, and the largest production plant for COVID-19 inactivated vaccines.

From design to construction, the workshop follows the relevant biosafety regulations and standards of China and the World Health Organization, and introduces experienced design teams from China and abroad. From building to maintaining, the production is in accordance with the high-level biosafety protection standard. The construction of the plant took only 2 months, and the construction was completed on April 15, 2020.

The construction of the high-level biosafety facilities and supporting laboratory complex of the Wuhan Institute of Biological Products of China National Biotech was completed on July 1. It strives to obtain relevant inspections and have production conditions as soon as possible.

The company says that China Biotech Group-Wuhan Institute of Biological Products will also become the world's only biological product R&D and production unit with a high-level biosafety R&D laboratory and production facility complex.

After the production plants of the two research institutes in Beijing and Wuhan are put into use, they will be able to guarantee that the annual production capacity of the COVID-19 inactivated vaccine will reach 220 million doses.


Recommend Submit

Media partners:
Multimedia Journalist | American Directory Netwo |